Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1991;83(3):179-88.
doi: 10.1007/BF01253388.

Some central pharmacological effects of the calcium channel antagonist flunarizine

Affiliations
Comparative Study

Some central pharmacological effects of the calcium channel antagonist flunarizine

A Czyrak et al. J Neural Transm Gen Sect. 1991.

Abstract

Our earlier studies showed that dihydropyridine calcium channel antagonists have some central pharmacological effects. Flunarizine is considered to be a calcium channel antagonist; therefore this study was aimed at investigating the effect of flunarizine (given in single doses of 5, 10 and 20 mg/kg p.o.) in behavioural models in which calcium channel antagonists of the dihydropyridine type were previously studied. Flunarizine inhibited the apomorphine-induced stereotypy and yawning behaviour in rats. It decreased the hypothermia induced by a low dose of apomorphine in mice, but not that one induced by high dose of it. The quinpirole-induced hypothermia was also reduced. In the tests used for evaluation of the effect on the serotonergic system, flunarizine decreased the 5-HTP-induced head twitches and partly antagonized the fenfluramine- and quipazine-induced hyperthermias (at a high ambient temperature). In the forced swimming test flunarizine was inactive in mice and rats. The obtained results indicate that flunarizine exerts central antagonistic effects on the dopaminergic and serotonergic systems and has no antidepressant activity. Flunarizine differs from calcium channel antagonists of the dihydropyridine type, which have no dopamine-antagonistic activity and show anti-depressant-like properties.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Pharmacol Chemother. 1963 Feb;20:106-20 - PubMed
    1. Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(2-3):165-73 - PubMed
    1. Adv Biochem Psychopharmacol. 1978;19:275-92 - PubMed
    1. Psychopharmacology (Berl). 1988;94(2):147-60 - PubMed
    1. Life Sci. 1986 Jun 30;38(26):2375-81 - PubMed

Publication types

MeSH terms